<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="782" width="593">
	<fontspec id="font0" size="11" family="AdvSMyr-SB" color="#000000"/>
	<fontspec id="font1" size="10" family="AdvSMyr-SB" color="#000000"/>
	<fontspec id="font2" size="9" family="AdvC2866" color="#000000"/>
	<fontspec id="font3" size="9" family="AdvPSMP13" color="#000000"/>
	<fontspec id="font4" size="9" family="AdvC2870" color="#000000"/>
	<fontspec id="font5" size="9" family="AdvC2867" color="#000000"/>
	<fontspec id="font6" size="9" family="AdvPS586B" color="#000000"/>
	<fontspec id="font7" size="8" family="AdvPSMy-R" color="#000000"/>
<text top="49" left="45" width="43" height="11" font="font0" id="p1_t1" reading_order_no="1" segment_no="1" tag_type="title">RESULTS</text>
<text top="65" left="45" width="74" height="10" font="font1" id="p1_t2" reading_order_no="2" segment_no="3" tag_type="title">Participant Flow</text>
<text top="78" left="45" width="243" height="8" font="font2" id="p1_t3" reading_order_no="3" segment_no="5" tag_type="text">A total of 590 parents of children were briefed; of these, 436</text>
<text top="89" left="45" width="243" height="8" font="font2" id="p1_t4" reading_order_no="4" segment_no="5" tag_type="text">parents consented to screening. Of the 320 children who were</text>
<text top="100" left="45" width="243" height="8" font="font2" id="p1_t5" reading_order_no="5" segment_no="5" tag_type="text">returned for screening, 135 (77 girls and 58 boys) were enrolled</text>
<text top="111" left="45" width="243" height="8" font="font2" id="p1_t6" reading_order_no="6" segment_no="5" tag_type="text">and randomized to one of the three dosage cohorts. Among</text>
<text top="122" left="45" width="243" height="8" font="font2" id="p1_t7" reading_order_no="7" segment_no="5" tag_type="text">these were 25 children who were initially disqualiﬁed owing to</text>
<text top="133" left="45" width="243" height="8" font="font2" id="p1_t8" reading_order_no="8" segment_no="5" tag_type="text">clinical malaria; however, they were subsequently enrolled after</text>
<text top="144" left="45" width="243" height="8" font="font2" id="p1_t9" reading_order_no="9" segment_no="5" tag_type="text">successful treatment and conﬁrmed cure. Of the 135 subjects</text>
<text top="155" left="45" width="243" height="8" font="font2" id="p1_t10" reading_order_no="10" segment_no="5" tag_type="text">who received the ﬁrst vaccination, ﬁve did not receive the</text>
<text top="166" left="45" width="243" height="8" font="font2" id="p1_t11" reading_order_no="11" segment_no="5" tag_type="text">second vaccination and another eight did not receive the third.</text>
<text top="177" left="45" width="243" height="8" font="font2" id="p1_t12" reading_order_no="12" segment_no="5" tag_type="text">Thus, 122 subjects received all three vaccinations; 83 of the 90</text>
<text top="188" left="45" width="243" height="8" font="font2" id="p1_t13" reading_order_no="13" segment_no="5" tag_type="text">subjects were randomized to receive FMP1/AS02A and 39 of the</text>
<text top="199" left="45" width="243" height="8" font="font2" id="p1_t14" reading_order_no="14" segment_no="5" tag_type="text">45 randomized to receive the rabies vaccine. The 13 incom-</text>
<text top="210" left="45" width="243" height="8" font="font2" id="p1_t15" reading_order_no="15" segment_no="5" tag_type="text">pletely vaccinated subjects were evenly distributed among the</text>
<text top="221" left="45" width="243" height="8" font="font2" id="p1_t16" reading_order_no="16" segment_no="5" tag_type="text">three dose cohorts (Figure 1). Because all of the 135 enrolled</text>
<text top="232" left="45" width="243" height="8" font="font2" id="p1_t17" reading_order_no="17" segment_no="5" tag_type="text">subjects received at least one vaccination, all were to be</text>
<text top="243" left="45" width="243" height="8" font="font2" id="p1_t18" reading_order_no="18" segment_no="5" tag_type="text">followed per protocol for the study duration and included in</text>
<text top="254" left="45" width="243" height="8" font="font2" id="p1_t19" reading_order_no="19" segment_no="5" tag_type="text">the safety analyses. Twenty-ﬁve subjects withdrew prematurely</text>
<text top="265" left="45" width="243" height="8" font="font2" id="p1_t20" reading_order_no="20" segment_no="5" tag_type="text">from the study, approximately 20% from each study arm; these</text>
<text top="276" left="45" width="243" height="8" font="font2" id="p1_t21" reading_order_no="21" segment_no="5" tag_type="text">withdrawals were also evenly distributed across cohorts. Twelve</text>
<text top="287" left="45" width="243" height="8" font="font2" id="p1_t22" reading_order_no="22" segment_no="5" tag_type="text">subjects had consent withdrawn by a parent or grandparent</text>
<text top="298" left="45" width="243" height="8" font="font2" id="p1_t23" reading_order_no="23" segment_no="5" tag_type="text">because of family discord regarding participation in the study;</text>
<text top="309" left="45" width="243" height="8" font="font2" id="p1_t24" reading_order_no="24" segment_no="5" tag_type="text">11 subjects migrated out of the study area; one subject attended</text>
<text top="320" left="45" width="243" height="8" font="font2" id="p1_t25" reading_order_no="25" segment_no="5" tag_type="text">the ﬁnal study visit during which the mother refused the blood</text>
<text top="331" left="45" width="243" height="8" font="font2" id="p1_t26" reading_order_no="26" segment_no="5" tag_type="text">draw; and one subject died. With the exception of the last, no</text>
<text top="342" left="45" width="243" height="8" font="font2" id="p1_t27" reading_order_no="27" segment_no="5" tag_type="text">subject was withdrawn from the study (as opposed to withheld</text>
<text top="353" left="45" width="175" height="8" font="font2" id="p1_t28" reading_order_no="28" segment_no="5" tag_type="text">from further vaccinations) because of an AE.</text>
<text top="370" left="45" width="55" height="10" font="font1" id="p1_t29" reading_order_no="29" segment_no="7" tag_type="title">Recruitment</text>
<text top="383" left="45" width="243" height="8" font="font2" id="p1_t30" reading_order_no="30" segment_no="8" tag_type="text">Recruiting and enrollment occurred from 25 July through 12</text>
<text top="394" left="45" width="243" height="8" font="font2" id="p1_t31" reading_order_no="31" segment_no="8" tag_type="text">September 2003. The study duration was approximately 12 mo</text>
<text top="405" left="45" width="238" height="8" font="font2" id="p1_t32" reading_order_no="32" segment_no="8" tag_type="text">for a subject with the last study visit on 19 September 2004.</text>
<text top="423" left="45" width="62" height="10" font="font1" id="p1_t33" reading_order_no="33" segment_no="10" tag_type="title">Baseline Data</text>
<text top="435" left="45" width="243" height="8" font="font2" id="p1_t34" reading_order_no="34" segment_no="11" tag_type="text">The study groups were comparable in baseline demography,</text>
<text top="446" left="45" width="243" height="8" font="font2" id="p1_t35" reading_order_no="35" segment_no="11" tag_type="text">height, weight, and vital signs (temperature, pulse, respiratory</text>
<text top="457" left="45" width="243" height="8" font="font2" id="p1_t36" reading_order_no="36" segment_no="11" tag_type="text">rate, and blood pressure). Baseline clinical laboratory meas-</text>
<text top="468" left="45" width="243" height="8" font="font2" id="p1_t37" reading_order_no="37" segment_no="11" tag_type="text">urements other than ALC were consistent across study arms;</text>
<text top="479" left="45" width="243" height="8" font="font2" id="p1_t38" reading_order_no="38" segment_no="11" tag_type="text">most measurements fell within the local normal range. Both</text>
<text top="490" left="45" width="243" height="8" font="font2" id="p1_t39" reading_order_no="39" segment_no="11" tag_type="text">study arms had a number of subjects outside of the normal</text>
<text top="501" left="45" width="243" height="8" font="font2" id="p1_t40" reading_order_no="40" segment_no="11" tag_type="text">range for ALC at the sampled timepoints, including prior to</text>
<text top="512" left="45" width="243" height="8" font="font2" id="p1_t41" reading_order_no="41" segment_no="11" tag_type="text">receipt of the ﬁrst vaccination, but none of these was deemed</text>
<text top="523" left="45" width="243" height="8" font="font2" id="p1_t42" reading_order_no="42" segment_no="11" tag_type="text">clinically signiﬁcant. Age, sex, height, weight, clinical labo-</text>
<text top="534" left="45" width="243" height="8" font="font2" id="p1_t43" reading_order_no="43" segment_no="11" tag_type="text">ratory values, and antibody to FMP1 prior to the ﬁrst</text>
<text top="545" left="45" width="243" height="8" font="font2" id="p1_t44" reading_order_no="44" segment_no="11" tag_type="text">vaccination are presented in Table 4 for the four study arms.</text>
<text top="563" left="45" width="86" height="10" font="font1" id="p1_t45" reading_order_no="45" segment_no="13" tag_type="title">Numbers Analyzed</text>
<text top="576" left="45" width="243" height="8" font="font2" id="p1_t46" reading_order_no="46" segment_no="14" tag_type="text">This study randomized 135 children (aged 12–47 mo) into</text>
<text top="587" left="45" width="243" height="8" font="font2" id="p1_t47" reading_order_no="47" segment_no="14" tag_type="text">three cohorts of 45 subjects, each consisting of 30 children</text>
<text top="598" left="45" width="165" height="8" font="font2" id="p1_t48" reading_order_no="48" segment_no="14" tag_type="text">who received FMP1/AS02A (10, 25, or 50</text>
<text top="597" left="213" width="5" height="8" font="font3" id="p1_t49" reading_order_no="49" segment_no="14" tag_type="text">l</text>
<text top="598" left="218" width="70" height="8" font="font2" id="p1_t50" reading_order_no="50" segment_no="14" tag_type="text">g of FMP1 in 0.1,</text>
<text top="609" left="45" width="243" height="8" font="font2" id="p1_t51" reading_order_no="51" segment_no="14" tag_type="text">0.25, or 0.50 mL of AS02A, respectively) and 15 children who</text>
<text top="620" left="45" width="243" height="8" font="font2" id="p1_t52" reading_order_no="52" segment_no="14" tag_type="text">received the comparator vaccine. Each cohort contained 15</text>
<text top="631" left="45" width="243" height="8" font="font2" id="p1_t53" reading_order_no="53" segment_no="14" tag_type="text">subjects, 10 receiving FMP1/AS02 and ﬁve the comparator, in</text>
<text top="642" left="45" width="243" height="8" font="font2" id="p1_t54" reading_order_no="54" segment_no="14" tag_type="text">each of three age groups (12–23, 24–35, and 36–47 mo, or 1-,</text>
<text top="653" left="45" width="243" height="8" font="font2" id="p1_t55" reading_order_no="55" segment_no="14" tag_type="text">2-, and 3-y-olds) for a total of 45 subjects in each age group</text>
<text top="664" left="45" width="243" height="8" font="font2" id="p1_t56" reading_order_no="56" segment_no="14" tag_type="text">distributed among the three cohorts. The comparator groups</text>
<text top="675" left="45" width="243" height="8" font="font2" id="p1_t57" reading_order_no="57" segment_no="14" tag_type="text">received rabies vaccine (Table 1). Each subject was to be</text>
<text top="686" left="45" width="243" height="8" font="font2" id="p1_t58" reading_order_no="58" segment_no="14" tag_type="text">studied for approximately 12 mo. Safety analyses were</text>
<text top="697" left="45" width="243" height="8" font="font2" id="p1_t59" reading_order_no="59" segment_no="14" tag_type="text">performed on an intention-to-treat cohort; immunogenicity</text>
<text top="708" left="45" width="243" height="8" font="font2" id="p1_t60" reading_order_no="60" segment_no="14" tag_type="text">analyses were performed on an according-to-protocol cohort</text>
<text top="719" left="45" width="241" height="8" font="font2" id="p1_t61" reading_order_no="61" segment_no="14" tag_type="text">that received all three vaccinations (106 subjects) (Figure 1).</text>
<text top="49" left="306" width="183" height="10" font="font1" id="p1_t62" reading_order_no="62" segment_no="2" tag_type="title">Outcomes and Estimation of Safety and</text>
<text top="62" left="306" width="66" height="10" font="font1" id="p1_t63" reading_order_no="63" segment_no="2" tag_type="title">Reactogenicity</text>
<text top="73" left="315" width="80" height="8" font="font4" id="p1_t64" reading_order_no="64" segment_no="4" tag_type="text">Solicited symptoms.</text>
<text top="73" left="399" width="150" height="8" font="font2" id="p1_t65" reading_order_no="65" segment_no="4" tag_type="text">Both the test article and comparator</text>
<text top="85" left="306" width="243" height="8" font="font2" id="p1_t66" reading_order_no="66" segment_no="4" tag_type="text">vaccines were well tolerated. No parent or child withdrew</text>
<text top="96" left="306" width="243" height="8" font="font2" id="p1_t67" reading_order_no="67" segment_no="4" tag_type="text">from the study for a vaccine-related side effect. Table 5</text>
<text top="107" left="306" width="243" height="8" font="font2" id="p1_t68" reading_order_no="68" segment_no="4" tag_type="text">summarizes the solicited signs and symptoms during the 7-d</text>
<text top="118" left="306" width="243" height="8" font="font2" id="p1_t69" reading_order_no="69" segment_no="4" tag_type="text">follow-up periods after vaccinations. Both local symptoms</text>
<text top="129" left="306" width="243" height="8" font="font2" id="p1_t70" reading_order_no="70" segment_no="4" tag_type="text">(pain and swelling) were deﬁned as vaccine-related AEs.</text>
<text top="140" left="306" width="243" height="8" font="font2" id="p1_t71" reading_order_no="71" segment_no="4" tag_type="text">Subjects in all cohorts who received FMP1/AS02A experi-</text>
<text top="151" left="306" width="243" height="8" font="font2" id="p1_t72" reading_order_no="72" segment_no="4" tag_type="text">enced more local symptoms than those who received the</text>
<text top="162" left="306" width="243" height="8" font="font2" id="p1_t73" reading_order_no="73" segment_no="4" tag_type="text">comparator, and a dose-related response was apparent. The</text>
<text top="174" left="306" width="243" height="8" font="font2" id="p1_t74" reading_order_no="74" segment_no="4" tag_type="text">largest percentage of these subjects experienced a local</text>
<text top="185" left="306" width="243" height="8" font="font2" id="p1_t75" reading_order_no="75" segment_no="4" tag_type="text">reaction immediately following the ﬁrst vaccination (46% of</text>
<text top="196" left="306" width="243" height="8" font="font2" id="p1_t76" reading_order_no="76" segment_no="4" tag_type="text">FMP1/AS02A subjects versus 2% of comparator subjects;</text>
<text top="207" left="306" width="4" height="8" font="font5" id="p1_t77" reading_order_no="77" segment_no="4" tag_type="text">p</text>
<text top="207" left="310" width="26" height="8" font="font2" id="p1_t78" reading_order_no="78" segment_no="4" tag_type="text">-value,</text>
<text top="207" left="340" width="7" height="8" font="font6" id="p1_t79" reading_order_no="79" segment_no="4" tag_type="text">,</text>
<text top="207" left="352" width="197" height="8" font="font2" id="p1_t80" reading_order_no="80" segment_no="4" tag_type="text">0.001); the percentages of subjects experiencing</text>
<text top="218" left="306" width="243" height="8" font="font2" id="p1_t81" reading_order_no="81" segment_no="4" tag_type="text">local symptoms during second and third vaccinations were</text>
<text top="229" left="306" width="243" height="8" font="font2" id="p1_t82" reading_order_no="82" segment_no="4" tag_type="text">lower in both study arms (respectively, 40% versus 9%;</text>
<text top="240" left="306" width="4" height="8" font="font5" id="p1_t83" reading_order_no="83" segment_no="4" tag_type="text">p</text>
<text top="240" left="310" width="26" height="8" font="font2" id="p1_t84" reading_order_no="84" segment_no="4" tag_type="text">-value,</text>
<text top="240" left="339" width="7" height="8" font="font6" id="p1_t85" reading_order_no="85" segment_no="4" tag_type="text">,</text>
<text top="240" left="350" width="108" height="8" font="font2" id="p1_t86" reading_order_no="86" segment_no="4" tag_type="text">0.001; and 37% versus 0%;</text>
<text top="240" left="461" width="4" height="8" font="font5" id="p1_t87" reading_order_no="87" segment_no="4" tag_type="text">p</text>
<text top="240" left="465" width="26" height="8" font="font2" id="p1_t88" reading_order_no="88" segment_no="4" tag_type="text">-value,</text>
<text top="240" left="494" width="7" height="8" font="font6" id="p1_t89" reading_order_no="89" segment_no="4" tag_type="text">,</text>
<text top="240" left="505" width="44" height="8" font="font2" id="p1_t90" reading_order_no="90" segment_no="4" tag_type="text">0.001). The</text>
<text top="251" left="306" width="243" height="8" font="font2" id="p1_t91" reading_order_no="91" segment_no="4" tag_type="text">most common local reaction at any time was pain at the site</text>
<text top="262" left="306" width="243" height="8" font="font2" id="p1_t92" reading_order_no="92" segment_no="4" tag_type="text">of injection. Up to 38% of subjects receiving FMP1/AS02A</text>
<text top="274" left="306" width="243" height="8" font="font2" id="p1_t93" reading_order_no="93" segment_no="4" tag_type="text">(percentages varied by dosage group) also experienced</text>
<text top="285" left="306" width="243" height="8" font="font2" id="p1_t94" reading_order_no="94" segment_no="4" tag_type="text">injection-site swelling; however, no subject receiving the</text>
<text top="296" left="306" width="135" height="8" font="font2" id="p1_t95" reading_order_no="95" segment_no="4" tag_type="text">comparator experienced swelling.</text>
<text top="307" left="315" width="234" height="8" font="font2" id="p1_t96" reading_order_no="96" segment_no="6" tag_type="text">No sequence- or dose-related trends were apparent for</text>
<text top="318" left="306" width="243" height="8" font="font2" id="p1_t97" reading_order_no="97" segment_no="6" tag_type="text">general solicited symptoms (Table 5). The most common</text>
<text top="329" left="306" width="243" height="8" font="font2" id="p1_t98" reading_order_no="98" segment_no="6" tag_type="text">general symptoms in both study arms were fever and loss of</text>
<text top="340" left="306" width="243" height="8" font="font2" id="p1_t99" reading_order_no="99" segment_no="6" tag_type="text">appetite. No instance of drowsiness occurred during any</text>
<text top="352" left="306" width="243" height="8" font="font2" id="p1_t100" reading_order_no="100" segment_no="6" tag_type="text">solicited symptom follow-up period. Fever was seen after</text>
<text top="363" left="306" width="243" height="8" font="font2" id="p1_t101" reading_order_no="101" segment_no="6" tag_type="text">vaccination in all dosage groups, with the highest rates being</text>
<text top="374" left="306" width="69" height="8" font="font2" id="p1_t102" reading_order_no="102" segment_no="6" tag_type="text">seen in the 50-</text>
<text top="373" left="376" width="5" height="8" font="font3" id="p1_t103" reading_order_no="103" segment_no="6" tag_type="text">l</text>
<text top="374" left="381" width="168" height="8" font="font2" id="p1_t104" reading_order_no="104" segment_no="6" tag_type="text">g dosage group. Loss of appetite and</text>
<text top="385" left="306" width="243" height="8" font="font2" id="p1_t105" reading_order_no="105" segment_no="6" tag_type="text">irritability/fussiness were seen at similar rates in all dosage</text>
<text top="396" left="306" width="145" height="8" font="font2" id="p1_t106" reading_order_no="106" segment_no="6" tag_type="text">groups and the comparator vaccine.</text>
<text top="407" left="315" width="234" height="8" font="font2" id="p1_t107" reading_order_no="107" segment_no="9" tag_type="text">Few subjects experienced grade 3 symptoms (Table 5). Grade</text>
<text top="418" left="306" width="243" height="8" font="font2" id="p1_t108" reading_order_no="108" segment_no="9" tag_type="text">3 pain at the injection site was seen sporadically with the</text>
<text top="429" left="306" width="204" height="8" font="font2" id="p1_t109" reading_order_no="109" segment_no="9" tag_type="text">second and third immunization in the 25- and 50-</text>
<text top="429" left="510" width="5" height="8" font="font3" id="p1_t110" reading_order_no="110" segment_no="9" tag_type="text">l</text>
<text top="429" left="515" width="34" height="8" font="font2" id="p1_t111" reading_order_no="111" segment_no="9" tag_type="text">g dosage</text>
<text top="440" left="306" width="243" height="8" font="font2" id="p1_t112" reading_order_no="112" segment_no="9" tag_type="text">groups of FMP1/AS02A. Grade 3 fever was seen sporadically in</text>
<text top="452" left="306" width="194" height="8" font="font2" id="p1_t113" reading_order_no="113" segment_no="9" tag_type="text">both the test article and the comparator vaccine.</text>
<text top="463" left="315" width="94" height="8" font="font4" id="p1_t114" reading_order_no="114" segment_no="12" tag_type="text">Unsolicited symptoms.</text>
<text top="463" left="415" width="134" height="8" font="font2" id="p1_t115" reading_order_no="115" segment_no="12" tag_type="text">Unsolicited symptoms were re-</text>
<text top="474" left="306" width="243" height="8" font="font2" id="p1_t116" reading_order_no="116" segment_no="12" tag_type="text">corded for 30 d following each vaccine administration and</text>
<text top="485" left="306" width="243" height="8" font="font2" id="p1_t117" reading_order_no="117" segment_no="12" tag_type="text">were categorized by a modiﬁed World Health Organization</text>
<text top="496" left="306" width="243" height="8" font="font2" id="p1_t118" reading_order_no="118" segment_no="12" tag_type="text">Adverse Reactions Terminology (WHOART) AE coding</text>
<text top="507" left="306" width="243" height="8" font="font2" id="p1_t119" reading_order_no="119" segment_no="12" tag_type="text">system. There were no differences by group or by cohort in</text>
<text top="518" left="306" width="243" height="8" font="font2" id="p1_t120" reading_order_no="120" segment_no="12" tag_type="text">the proportions of subjects experiencing an unsolicited</text>
<text top="529" left="306" width="243" height="8" font="font2" id="p1_t121" reading_order_no="121" segment_no="12" tag_type="text">symptom. All but one of the enrolled children experienced</text>
<text top="541" left="306" width="243" height="8" font="font2" id="p1_t122" reading_order_no="122" segment_no="12" tag_type="text">at least one unsolicited symptom during a follow-up period,</text>
<text top="552" left="306" width="243" height="8" font="font2" id="p1_t123" reading_order_no="123" segment_no="12" tag_type="text">and most experienced an unsolicited symptom during each of</text>
<text top="563" left="306" width="243" height="8" font="font2" id="p1_t124" reading_order_no="124" segment_no="12" tag_type="text">the three follow-up periods (77%–97% for FMP1/AS02A and</text>
<text top="574" left="306" width="243" height="8" font="font2" id="p1_t125" reading_order_no="125" segment_no="12" tag_type="text">80%–100% for the comparator). The most common unsoli-</text>
<text top="585" left="306" width="243" height="8" font="font2" id="p1_t126" reading_order_no="126" segment_no="12" tag_type="text">cited symptoms were upper respiratory tract infections</text>
<text top="596" left="306" width="83" height="8" font="font2" id="p1_t127" reading_order_no="127" segment_no="12" tag_type="text">(URTIs) and malaria.</text>
<text top="607" left="315" width="234" height="8" font="font2" id="p1_t128" reading_order_no="128" segment_no="15" tag_type="text">Approximately 80% of subjects in each study arm</text>
<text top="618" left="306" width="243" height="8" font="font2" id="p1_t129" reading_order_no="129" segment_no="15" tag_type="text">experienced at least one URTI during the three 30-d</text>
<text top="630" left="306" width="243" height="8" font="font2" id="p1_t130" reading_order_no="130" segment_no="15" tag_type="text">postimmunization follow-up periods. There was no indica-</text>
<text top="641" left="306" width="243" height="8" font="font2" id="p1_t131" reading_order_no="131" segment_no="15" tag_type="text">tion that vaccinated groups had any increased risk of</text>
<text top="652" left="306" width="110" height="8" font="font2" id="p1_t132" reading_order_no="132" segment_no="15" tag_type="text">developing clinical malaria.</text>
<text top="663" left="315" width="234" height="8" font="font2" id="p1_t133" reading_order_no="133" segment_no="16" tag_type="text">For unsolicited symptoms, vaccine relatedness was deter-</text>
<text top="674" left="306" width="243" height="8" font="font2" id="p1_t134" reading_order_no="134" segment_no="16" tag_type="text">mined by temporal relationship to a vaccination with absence</text>
<text top="685" left="306" width="243" height="8" font="font2" id="p1_t135" reading_order_no="135" segment_no="16" tag_type="text">of any reasonably explanatory comorbidity. Very few vaccine-</text>
<text top="696" left="306" width="243" height="8" font="font2" id="p1_t136" reading_order_no="136" segment_no="16" tag_type="text">related unsolicited symptoms occurred during the post-</text>
<text top="707" left="306" width="243" height="8" font="font2" id="p1_t137" reading_order_no="137" segment_no="16" tag_type="text">immunization follow-up period (ﬁve and one among FMP1/</text>
<text top="719" left="306" width="243" height="8" font="font2" id="p1_t138" reading_order_no="138" segment_no="16" tag_type="text">AS02A and comparator recipients, respectively). These</text>
<text top="742" left="45" width="85" height="7" font="font7" id="p1_t139" reading_order_no="139" segment_no="17" tag_type="text">www.plosclinicaltrials.org</text>
<text top="742" left="471" width="78" height="7" font="font7" id="p1_t140" reading_order_no="141" segment_no="18" tag_type="text">November | 2006 | e32</text>
<text top="742" left="289" width="16" height="7" font="font7" id="p1_t141" reading_order_no="140" segment_no="19" tag_type="text">0006</text>
<text top="26" left="387" width="162" height="7" font="font7" id="p1_t142" reading_order_no="0" segment_no="0" tag_type="title">Pediatric MSP-1 Phase Ib Trial in Western Kenya</text>
</page>
</pdf2xml>
